French Guiana Wellness Network
SEE OTHER BRANDS

Keeping up with health and wellness news from French Guiana

French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on April 8, 2025

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen Appoints Jacob Johnson As Vice President Investor Relations

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with …

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: …

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”), today announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once- …

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of …

EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer

EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer

BRANFORD, Conn. and NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing next-generation T cell engager biotherapeutics to overcome cancer cell resistance to current immunotherapies, today announced …

Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia

Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia

EMA orphan drug designation is awarded to drugs intended to treat rare diseases that are life-threatening or chronically debilitating Preeclampsia, a serious obstetric complication, is a leading cause of near-term morbidity and mortality for mothers and …

Microbix Provides Business Updates

Microbix Provides Business Updates

MISSISSAUGA, Ontario, April 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter, provides an update on U.S. and reciprocal tariff outcomes as …

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the …

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025

POMPANO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that …

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of …

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce …

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all manufactured batches PAS approval follows recent FDA approval of new formulation, EGRIFTA WR™ MONTREAL, April 08, 2025 (GLOBE NEWSWIRE) -- …

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in …

Routine medical appointments and cancer screenings head in the wrong direction

Routine medical appointments and cancer screenings head in the wrong direction

ALEXANDRIA, Va., April 08, 2025 (GLOBE NEWSWIRE) -- When was the last time you saw your doctor? There’s been a change in how often U.S. adults are going to routine medical appointments and cancer screenings, and according to the Prevent Cancer Foundation’s …

Tilray Brands Reports Q3 Fiscal 2025 Financial Results

Tilray Brands Reports Q3 Fiscal 2025 Financial Results

Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. …

Theratechnologies reçoit l’approbation de la FDA pour le supplément d’approbation préalable [PAS] relatif à sa demande d’un supplément à la licence de produit biologique (sBLA) pour EGRIFTA SV(MD)

Theratechnologies reçoit l’approbation de la FDA pour le supplément d’approbation préalable [PAS] relatif à sa demande d’un supplément à la licence de produit biologique (sBLA) pour EGRIFTA SV(MD)

L’approbation de la FDA permet une distribution sans restriction d’EGRIFTA SVMD, levant ainsi l'incertitude concernant tous les lots fabriqués L’approbation du PAS fait suite à l’approbation récente de la nouvelle formulation, EGRIFTA WRMC MONTRÉAL, 08 avr …

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Telix Announces Cardinal Health for Gozellix Commercial Distribution

MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its …

Teladoc Health Introduces Next Generation Cardiometabolic Health Program

Teladoc Health Introduces Next Generation Cardiometabolic Health Program

PURCHASE, NY, April 08, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today introduced its next generation Cardiometabolic Health Program to improve population health and prevent the progression of diabetes, …

Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development

Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development

Steen Lisby, M.D., D.MSc. joins as Chief Medical Officer Jesper Valbjørn, M.Sc. joins as Senior Vice President CMC Ongoing team expansion at Myricx Bio's new facilities in London’s Canary Wharf biotech hub following 2024 £90 million ($114 million) series A …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service